Ipamorelin
Ipamorelin is a peptide, indexed here under Growth hormone secretagogues.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Growth hormone secretagogues |
| CAS registry number | 170851-70-4[1] |
| PubChem CID | 9831659[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C38H49N9O5[1] |
| Molecular weight | 711.9 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Ipamorelin is described in a 1998 European Journal of Endocrinology paper as the first selective growth hormone secretagogue. A 1998 Journal of Medicinal Chemistry paper reports a series of growth hormone-releasing peptides derived from it.
The retrieved literature also covers a ghrelin-mimetic framing in a 2009 Journal of Pharmacology and Experimental Therapeutics report in a rodent model of postoperative ileus, a 2014 International Journal of Colorectal Disease proof-of-concept study, and a 2015 Drug Testing and Analysis paper on urinary metabolites of growth hormone releasing peptides after nasal administration.
[3, 4, 5, 6, 7]Reported mechanism
A selective growth hormone secretagogue and ghrelin mimetic, acting at the growth hormone secretagogue receptor.
[3, 5]Stated in the titles of the cited 1998 European Journal of Endocrinology and 2009 Journal of Pharmacology and Experimental Therapeutics papers.
Targets named in the cited records: growth hormone secretagogue receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Ipamorelin appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- NNC 26-0161
Where this page sits
Research records
Cited research records for Ipamorelin, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include Ipamorelin
Compounds indexed next to it
- GHRP-6 — Growth hormone secretagogues
- Hexarelin — Growth hormone secretagogues
- Ibutamoren — Growth hormone secretagogues
- AOD9604 — Growth hormone secretagogues
- GHRP-2 — Growth hormone secretagogues
Named targets in the cited records
Class page: Growth hormone secretagogues. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Ipamorelin?
Ipamorelin is described in a 1998 European Journal of Endocrinology paper as the first selective growth hormone secretagogue. A 1998 Journal of Medicinal Chemistry paper reports a series of growth hormone-releasing peptides derived from it.
Which class is Ipamorelin indexed under?
Ipamorelin is indexed under Growth hormone secretagogues. Growth hormone secretagogues are compounds that act at the growth hormone secretagogue receptor, the receptor for ghrelin, rather than at the growth hormone releasing hormone receptor.
What does the FDA application register show for Ipamorelin?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 9831659, Ipamorelin. PubChem, National Library of Medicine (2026). pubchem:9831659
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:ipamorelin
- Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol (1998). pmid:9849822
- A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. J Med Chem (1998). pmid:9733495
- Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther (2009). pmid:19289567
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis (2014). pmid:25331030
- Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Test Anal (2015). pmid:25869809
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.